{"id":305203,"date":"2024-04-17T00:00:00","date_gmt":"2024-04-17T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidid0023-biopharma-hospital-treated-gram-negative-infections-epidemiology-emerging-markets\/"},"modified":"2026-04-17T23:22:05","modified_gmt":"2026-04-17T23:22:05","slug":"epidid0023-biopharma-hospital-treated-gram-negative-infections-epidemiology-emerging-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidid0023-biopharma-hospital-treated-gram-negative-infections-epidemiology-emerging-markets\/","title":{"rendered":"Hospital-Treated Gram-Negative Infections &#8211; Epidemiology &#8211; Emerging Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of hospital-treated gram-negative infections (<abbr title=\"hospital-treated\">HT<\/abbr>&#8211;<abbr title=\"gram-negative infection\">GNI<\/abbr>s) comprises epidemiological estimates of nine types of infections in the emerging pharmaceutical markets (Brazil, rural China, urban China, rural India, urban India, Mexico, Russia, South Korea, and Turkey). The nine kinds of infections are urinary tract infections (<abbr title=\"urinary tract infection\">UTI<\/abbr>s), bloodstream infections (<abbr title=\"bloodstream infection\">BSI<\/abbr>s), complicated intra-abdominal infections (<abbr title=\"complicated intra-abdominal infection\">cIAI<\/abbr>s), complicated skin and skin structure infections (<abbr title=\"complicated skin and skin structure infection\">cSSSI<\/abbr>s), surgical-site infections (<abbr title=\"surgical-site infection\">SSI<\/abbr>s), nosocomial pneumonia (<abbr title=\"nosocomial pneumonia\">NP<\/abbr>), hospital-acquired pneumonia (<abbr title=\"hospital-acquired pneumonia\">HAP<\/abbr>), healthcare-acquired pneumonia (<abbr title=\"healthcare-acquired pneumonia\">HCAP<\/abbr>), and ventilator-associated pneumonia (<abbr title=\"ventilator-associated pneumonia\">VAP<\/abbr>). We report the incidence of <abbr title=\"hospital-treated\">HT<\/abbr>&#8211;<abbr title=\"gram-negative infection\">GNI<\/abbr>s for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 10 years for the emerging pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"hospital-treated\">HT<\/abbr>&#8211;<abbr title=\"gram-negative infection\">GNI<\/abbr> forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"hospital-treated\">HT<\/abbr>&#8211;<abbr title=\"gram-negative infection\">GNI<\/abbr>s over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS <\/span>Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 42 <abbr title=\"hospital-treated\">HT<\/abbr>&#8211;<abbr title=\"gram-negative infection\">GNI<\/abbr> patient populations, including the following:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed gram-negative <abbr title=\"urinary tract infection\">UTI<\/abbr> hospitalization events due to <em>E. coli.<\/em><\/li>\n<li>Diagnosed gram-negative <abbr title=\"surgical-site infection\">SSI<\/abbr> hospitalization events due to <em>Pseudomonas spp.<\/em><\/li>\n<li>Diagnosed gram-negative <abbr title=\"bloodstream infection\">BSI<\/abbr> hospitalization events due to <em>E. coli.<\/em><\/li>\n<li>Diagnosed gram-negative <abbr title=\"complicated skin and skin structure infection\">cSSSI<\/abbr> hospitalization events due to <em>Acinetobacter spp.<\/em><\/li>\n<li>Diagnosed gram-negative <abbr title=\"complicated intra-abdominal infection\">cIAI<\/abbr> hospitalization events due to <em>Klebsiella spp.<\/em><\/li>\n<li>Diagnosed gram-negative <abbr title=\"nosocomial pneumonia\">NP<\/abbr> hospitalization events due to <em>Pseudomonas spp.<\/em><\/li>\n<\/ul>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-305203","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305203\/revisions"}],"predecessor-version":[{"id":305695,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305203\/revisions\/305695"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=305203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}